151 related articles for article (PubMed ID: 25329662)
21. Futility interim monitoring with control of type I and II error probabilities using the interim Z-value or confidence limit.
Lachin JM
Clin Trials; 2009 Dec; 6(6):565-73. PubMed ID: 19933716
[TBL] [Abstract][Full Text] [Related]
22. Comparisons of test statistics arising from marginal analyses of multivariate survival data.
Li QH; Lagakos SW
Lifetime Data Anal; 2004 Dec; 10(4):389-405. PubMed ID: 15690992
[TBL] [Abstract][Full Text] [Related]
23. Sample size determination based on rank tests in clinical trials.
Wang H; Chen B; Chow SC
J Biopharm Stat; 2003 Nov; 13(4):735-51. PubMed ID: 14584719
[TBL] [Abstract][Full Text] [Related]
24. On design considerations and randomization-based inference for community intervention trials.
Gail MH; Mark SD; Carroll RJ; Green SB; Pee D
Stat Med; 1996 Jun; 15(11):1069-92. PubMed ID: 8804140
[TBL] [Abstract][Full Text] [Related]
25. A flexible multi-domain test with adaptive weights and its application to clinical trials.
Zhao Y; Yu Q; Lake SL
Pharm Stat; 2020 May; 19(3):315-325. PubMed ID: 31886602
[TBL] [Abstract][Full Text] [Related]
26. Increasing the sample size at interim for a two-sample experiment without Type I error inflation.
Dunnigan K; King DW
Pharm Stat; 2010; 9(4):280-7. PubMed ID: 19764040
[TBL] [Abstract][Full Text] [Related]
27. Bayesian multiple testing for two-sample multivariate endpoints.
Gönen M; Westfall PH; Johnson W
Biometrics; 2003 Mar; 59(1):76-82. PubMed ID: 12762443
[TBL] [Abstract][Full Text] [Related]
28. Design and analysis for survival data under order restrictions with a modified logrank test.
Liu PY; Tsai WY; Wolf M
Stat Med; 1998 Jul; 17(13):1469-79. PubMed ID: 9695192
[TBL] [Abstract][Full Text] [Related]
29. Adaptive Designs with Discrete Test Statistics and Consideration of Overrunning.
Schmidt R; Burkhardt B; Faldum A
Methods Inf Med; 2015; 54(5):434-46. PubMed ID: 26429500
[TBL] [Abstract][Full Text] [Related]
30. A multiclass multivariate group comparison test: Application to drug safety.
Tohme M; Lengelle R; Freytag V
Annu Int Conf IEEE Eng Med Biol Soc; 2010; 2010():4711-4. PubMed ID: 21096014
[TBL] [Abstract][Full Text] [Related]
31. A hybrid procedure for detecting global treatment effects in multivariate clinical trials: theory and applications to fMRI studies.
Minas G; Rigat F; Nichols TE; Aston JA; Stallard N
Stat Med; 2012 Feb; 31(3):253-68. PubMed ID: 22170084
[TBL] [Abstract][Full Text] [Related]
32. Heterogeneous treatment effects in stratified clinical trials with time-to-event endpoints.
Beisel C; Benner A; Kunz C; Kopp-Schneider A
Biom J; 2017 May; 59(3):511-530. PubMed ID: 28263395
[TBL] [Abstract][Full Text] [Related]
33. Joint one-sided and two-sided simultaneous confidence intervals.
Braat S; Gerhard D; Hothorn LA
J Biopharm Stat; 2008; 18(2):293-306. PubMed ID: 18327722
[TBL] [Abstract][Full Text] [Related]
34. Power and sample size when multiple endpoints are considered.
Senn S; Bretz F
Pharm Stat; 2007; 6(3):161-70. PubMed ID: 17674404
[TBL] [Abstract][Full Text] [Related]
35. Applying univariate vs. multivariate statistics to investigate therapeutic efficacy in (pre)clinical trials: A Monte Carlo simulation study on the example of a controlled preclinical neurotrauma trial.
Todorov H; Searle-White E; Gerber S
PLoS One; 2020; 15(3):e0230798. PubMed ID: 32214370
[TBL] [Abstract][Full Text] [Related]
36. Power and sample size evaluation for the Cochran-Mantel-Haenszel mean score (Wilcoxon rank sum) test and the Cochran-Armitage test for trend.
Lachin JM
Stat Med; 2011 Nov; 30(25):3057-66. PubMed ID: 22006667
[TBL] [Abstract][Full Text] [Related]
37. Non-inferiority trials: the 'at least as good as' criterion.
Laster LL; Johnson MF
Stat Med; 2003 Jan; 22(2):187-200. PubMed ID: 12520556
[TBL] [Abstract][Full Text] [Related]
38. Power calculation for clinical trials when the outcome is a composite ranking of survival and a nonfatal outcome.
McMahon RP; Harrell FE
Control Clin Trials; 2000 Aug; 21(4):305-12. PubMed ID: 10913806
[TBL] [Abstract][Full Text] [Related]
39. Optimization of adaptive designs: efficiency evaluation.
Menon S; Chang M
J Biopharm Stat; 2012; 22(4):641-61. PubMed ID: 22651106
[TBL] [Abstract][Full Text] [Related]
40. Resampling in multiple-dose factorial designs.
Frommolt P; Hellmich M
Biom J; 2009 Dec; 51(6):915-31. PubMed ID: 20029896
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
